Download PDF

1. Company Snapshot

1.a. Company Description

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs.


The company was formerly known as Encarta Therapeutics, Inc.and changed its name to Arcellx, Inc.in January 2016.


Arcellx, Inc.was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.

Show Full description

1.b. Last Insights on ACLX

Arcellx, Inc.'s recent performance was positively driven by favorable analyst sentiment, with a consensus recommendation of "Moderate Buy" from twelve ratings firms, including eight buy recommendations. The company's presentation at the Morgan Stanley 23rd Annual Global Healthcare Conference highlighted its growth prospects. Although the Q3 earnings report showed a loss of $0.99 per share, slightly missing revenue estimates, the company is expected to beat earnings estimates in its upcoming report, according to Zacks Consensus Estimate.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Nov -25

Source: defenseworld.net

Card image cap

Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates

Nov -05

Source: zacks.com

Card image cap

Arcellx, Inc. (NASDAQ:ACLX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Oct -31

Source: defenseworld.net

Card image cap

Arcellx, Inc. (ACLX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Oct -30

Source: zacks.com

Card image cap

Arcellx, Inc. (ACLX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep -10

Source: seekingalpha.com

Card image cap

Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025

Aug -08

Source: seekingalpha.com

Card image cap

Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates

Aug -07

Source: zacks.com

Card image cap

Arcellx (ACLX) Q2 Revenue Drops 72%

Aug -07

Source: fool.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (25.40%)

6. Segments

Cell Therapies

Expected Growth: 25.4%

Growing demand for cell therapies, increasing cancer prevalence, and advancements in gene editing technologies drive the market growth. Arcellx's innovative approach to producing antibodies through genetically modified cells offers a potential cure, further fueling growth.

7. Detailed Products

Arcellx's CART-ddBCMA

A novel, investigational cell therapy designed to target and eliminate cancer cells that express the B-cell maturation antigen (BCMA), a protein highly expressed on multiple myeloma cells.

Arcellx's CART-iX cells

A type of chimeric antigen receptor (CAR) T-cell therapy that targets CD19, a protein expressed on the surface of B cells, for the treatment of B-cell malignancies.

Arcellx's CART-BCMA cells

A CAR T-cell therapy that targets BCMA, a protein highly expressed on multiple myeloma cells, for the treatment of multiple myeloma.

Arcellx's D-Domain antibodies

A novel class of antibodies that can be used to target specific proteins on the surface of cancer cells, enabling the development of new cancer therapies.

8. Arcellx, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Arcellx, Inc. operates in the biotechnology industry, which is characterized by high research and development costs. This makes it difficult for new entrants to develop substitutes, reducing the threat of substitutes.

Bargaining Power Of Customers

Arcellx, Inc. primarily sells its products to pharmaceutical companies, which have limited bargaining power due to the specialized nature of the products.

Bargaining Power Of Suppliers

Arcellx, Inc. relies on a few key suppliers for raw materials and equipment. While these suppliers have some bargaining power, Arcellx's strong relationships and diversified supply chain mitigate this risk.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to enter the market.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Arcellx, Inc. faces intense competition from companies such as Celgene, Gilead Sciences, and Novartis.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 16.75%
Debt Cost 4.24%
Equity Weight 83.25%
Equity Cost 5.08%
WACC 4.94%
Leverage 20.11%

11. Quality Control: Arcellx, Inc. passed 5 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Royalty Pharma

A-Score: 6.2/10

Value: 4.9

Growth: 3.8

Quality: 7.4

Yield: 4.0

Momentum: 8.5

Volatility: 9.0

1-Year Total Return ->

View Full Report
Stock-Card
Exelixis

A-Score: 5.8/10

Value: 3.4

Growth: 7.9

Quality: 9.2

Yield: 0.0

Momentum: 9.5

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Corcept Therapeutics

A-Score: 4.8/10

Value: 0.3

Growth: 8.0

Quality: 8.8

Yield: 0.0

Momentum: 10.0

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
Novavax

A-Score: 3.9/10

Value: 7.1

Growth: 5.4

Quality: 7.2

Yield: 0.0

Momentum: 2.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Arcellx

A-Score: 3.9/10

Value: 6.0

Growth: 5.7

Quality: 5.0

Yield: 0.0

Momentum: 3.0

Volatility: 4.0

1-Year Total Return ->

View Full Report
Stock-Card
Alpine Immune Sciences

A-Score: 3.8/10

Value: 6.0

Growth: 6.6

Quality: 4.0

Yield: 0.0

Momentum: 5.0

Volatility: 1.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

69.56$

Current Price

69.56$

Potential

-0.00%

Expected Cash-Flows